Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis?

  • A.R. Giardina | office@pagepress.org
  • A. Accardo-Palumbo
  • F. Ciccia
  • A. Ferrante
  • A. Principato
  • R. Impastato
  • G. Triolo

Abstract

Biological therapeutic agents neutralising tumour necrosis factor (TNF) are highly active in treating chronic inflammatory diseases, such as Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, uveitis, and psoriasis (1-3). From the beginning, side effects of TNF neutralisation - mostly infectious complications - were recognized, the most important being, however, pulmonary tuberculosis infections (4).

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Statistics
  • Abstract views: 1099

  • PDF: 838
How to Cite
Giardina, A., Accardo-Palumbo, A., Ciccia, F., Ferrante, A., Principato, A., Impastato, R., & Triolo, G. (1). Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis?. Reumatismo, 61(1), 21-26. https://doi.org/10.4081/reumatismo.2009.21

Most read articles by the same author(s)